Please ensure Javascript is enabled for purposes of website accessibility

NeoGenomics Reports Strong Growth but Gives a Weak Profit Outlook

By Jim Crumly – Feb 27, 2020 at 2:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Advances in precision medicine continue to propel the leader in oncology testing services.

NeoGenomics Laboratories (NEO -2.92%), the leading oncology testing company, reported strong growth in the fourth quarter but gave muted profit guidance for the next quarter, and shares fell 10%. Revenue increased 39.7% to $106.9 million, and the company earned $0.06 per share, compared with break-even results in the period a year ago. Analysts were expecting the company to earn $0.06 on revenue of $104.2 million.

Revenue from the company's clinical services division, which provides laboratory services for oncologists, pathologists, and hospitals, increased 41.7% to $93.4 million. The pharma services division, which supports research and development by pharmaceutical companies, grew revenue 27.5% to $13.5 million, and reported an increase in backlog of 31.8% to $130.3 million. Much of the overall revenue growth came from an acquisition, but the company said in the conference call that organic revenue growth exceeded 20%.

NeoGenomics has been investing in its capabilities to offer next-generation gene sequencing, which is increasingly being used in precision medicine to identify cancers and determine the best treatment. The company highlighted particular strength in next-generation and molecular testing, which grew 50% in the quarter and helped grow clinical division revenue per test by 11%.

Image of a DNA molecule in a test tube.

Image source: Getty Images.

NeoGenomics forecast full year 2020 revenue between $464 million and $474 million, 15% growth at the midpoint and above the analyst consensus estimate of $448 million. But CEO Doug VanOort said that profits in the first quarter will be significantly below what the company would normally expect, due to the timing of some large projects by pharma customers that won't be starting up until late March or April.

Profits will also be reduced as NeoGenomics invests in a newly formed informatics division, which will provide clinical decision support to physicians treating cancer patients, and will create a new source of revenue beginning later this year for this leader in the precision treatment of cancer.

Jim Crumly owns shares of NeoGenomics, Inc. The Motley Fool owns shares of and recommends NeoGenomics, Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NeoGenomics, Inc. Stock Quote
NeoGenomics, Inc.
NEO
$8.66 (-2.92%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.